Valuation: Petros Pharmaceuticals, Inc.

Market Cap 138K 123K 113K 103K 195K 12.91M 199K 1.35M 539K 6.91M 517K 506K 21.77M P/E 2024
-0.12x
P/E 2025 -0.01x
Enterprise Value -5M -4.46M -4.11M -3.73M -7.06M -469M -7.24M -49.12M -19.58M -251M -18.76M -18.36M -790M EV / Sales 2024
1.49x
EV / Sales 2025 -
Free-Float
74.41%
Yield 2024 *
-
Yield 2025 -
1 day+4.27%
1 week+65.00%
Current month+65.00%
3 months+3.12%
6 months-54.89%
Current year-58.49%
1 week 0
Extreme 0.0021
0
1 month 0
Extreme 0.001825
0
Current year 0
Extreme 0.001825
0.01
1 year 0
Extreme 0.0017
0.02
3 years 0
Extreme 0.0017
56.75
5 years 0
Extreme 0.0017
1,300
10 years 0
Extreme 0.0017
1,489.98
Manager TitleAgeSince
Director of Finance/CFO 66 -
President 49 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
6/5/26 Free

Director

1,875,000 4.4251%
1/2/26 Free

Director

500,000 1.1800%
1/2/26 Free

Chairperson

500,000 1.1800%
Change 5-day change 1-year change 3-year change Capi.($)
+4.27%+65.00%-84.72%-99.99% 132K
+3.87%+3.53%+26.07%+58.84% 257B
+2.12%+1.24%+11.99%+19.46% 162B
+1.71%+6.61%-17.76%+65.71% 157B
+2.97%+4.86%-55.99%-15.52% 61.96B
+2.52%+13.80%+25.57%+58.08% 58.73B
-3.36%+0.63%-0.30%-11.16% 55.42B
+3.10%+3.03%+22.78%+64.70% 49.27B
+0.88%-2.10%+3.91%+57.83% 49.18B
+4.17%+3.02%+28.25%+86.34% 44.96B
Average +1.44%+7.23%-4.02%+28.43% 90B
Weighted average by Cap. +0.86%+1.48%+7.22%+45.05%

Financials

2024 2025
Net sales 5.11M 4.56M 4.2M 3.81M 7.22M 479M 7.4M 50.23M 20.02M 257M 19.19M 18.78M 808M -
Net income -14.32M -12.78M -11.76M -10.67M -20.23M -1.34B -20.73M -141M -56.08M -719M -53.74M -52.59M -2.26B 1.91M 1.71M 1.57M 1.43M 2.7M 179M 2.77M 18.8M 7.49M 96.03M 7.18M 7.03M 302M
Net Debt 3.68M 3.28M 3.02M 2.74M 5.19M 345M 5.32M 36.12M 14.4M 184M 13.8M 13.5M 581M -5.14M -4.59M -4.22M -3.83M -7.26M -481M -7.44M -50.47M -20.12M -258M -19.28M -18.87M -812M
Projected Income Statement - Annual - Petros Pharmaceuticals, Inc.
Logo Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Employees
3
Date Price Change Volume
26-11-09 $0.003250 +4.27% 142,127
26-11-06 $0.003117 +0.55% 120,002
26-11-05 $0.003100 +11.11% 170,162
26-11-04 $0.002790 +32.86% 33,521
26-11-03 $0.002100 -40.00% 90,578

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Petros Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PTPI Stock